Symbol | Exchange | Currency |
|---|
Pre-Open Stock Movers:Adagio Therapeutics, Inc. (NASDAQ:ADGI) 50% HIGHER; ADG20 Met Primary Endpoints Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19Chewy...
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Oil & Gas, Utilities and Financials sectors led shares lower. At the close in NYSE, the Dow...
Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Utilities, Technology and Telecoms sectors led shares higher. At the close in NYSE, the Dow...
Investors will focus on pipeline updates when Israel-based clinical-stage immunotherapy company, Enlivex Therapeutics (NASDAQ:ENLV), Ltd ENLV, reports results for the three months...
Geron Corporation (NASDAQ:GERN) incurred a loss of 15 cents per share in fourth-quarter 2019, narrower than the Zacks Consensus Estimate of a loss of 20 cents. In the year-ago...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the FDA has granted Breakthrough Therapy designation to its leukemia drug Tibsovo (ivosidenib) for the treatment of...
Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).The Company has completed the evaluation of safety, tolerability, pharmacokinetics and pharmacodynamic effects of Imetelstat in its Phase I trials.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 166.06 | 169.39 | 165.78 | -3.33 | -1.97% | 1.04M | NASDAQ | |||
| 99.61 | 102.86 | 98.97 | -5.78 | -5.48% | 532.12K | NYSE | |||
| 74.83 | 74.92 | 71.60 | +1.16 | +1.58% | 31.68M | NASDAQ | |||
| 158.35 | 158.79 | 146.84 | +8.40 | +5.60% | 2.26M | NASDAQ | |||
| 50.97 | 51.89 | 50.71 | -1.34 | -2.57% | 4.12M | NYSE | |||
| 115.81 | 115.98 | 112.20 | -0.19 | -0.16% | 6.88M | NYSE | |||
| 6.67 | 7.16 | 6.60 | -0.76 | -10.16% | 3.19M | NYSE | |||
| 45.16 | 46.85 | 44.68 | -2.03 | -4.30% | 124.14K | NYSE | |||
| 33.47 | 34.37 | 33.08 | -2.10 | -5.90% | 2.43M | NYSE | |||
| 102.89 | 103.06 | 100.16 | +1.71 | +1.69% | 2.17M | NYSE | |||
| 0.1249 | 0.1364 | 0.1209 | -0.0115 | -8.43% | 652.35K | NYSE | |||
| 0.978 | 1.02 | 0.9577 | -0.0620 | -5.96% | 1.80M | NYSE | |||
| 45.14 | 47.06 | 45.03 | -2.27 | -4.79% | 1.13M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.429 | 1.43 | 1.29 | +0.089 | +6.66% | 1.66M | NASDAQ |